Class Decertification Stands In Pa. Neurontin Suit

Law360, New York (January 20, 2010, 3:51 PM EST) -- A Pennsylvania appeals court has affirmed a state court's decision to decertify a class action accusing Pfizer Inc. of marketing its blockbuster epilepsy drug Neurontin for off-label uses, but has restored a dismissed breach of warranty claim in the case.

A three-judge panel in the Superior Court of Pennsylvania on Tuesday ruled that the Philadelphia County Court of Common Pleas correctly decertfied a class of Pennsylvania Neurontin purchasers because the plaintiffs failed to meet commonality and typicality requirements, but found that the court erred in concurrently...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.